• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Keros Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:02:46 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email
    kros-20250506
    0001664710FALSE00016647102025-05-062025-05-060001664710us-gaap:CommonStockMember2025-05-062025-05-060001664710us-gaap:PreferredStockMember2025-05-062025-05-06

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM 8-K 
     
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): May 6, 2025
     
     
    Keros Therapeutics, Inc.
    (Exact name of registrant as specified in its charter)
     
     
     
    Delaware 001-39264 81-1173868
    (state or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (I.R.S. Employer
    Identification No.)
    1050 Waltham Street, Suite 302
    Lexington, Massachusetts
     02421
    (Address of principal executive offices) (Zip Code)
    Registrant’s telephone number, including area code: (617) 314-6297
     
    Not applicable
    (Former name or former address, if changed since last report.)
     
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
     
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 



     
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class 
    Trading
    Symbol
     
    Name of each exchange
    on which registered
    Common Stock, $0.0001 par value per share KROS The Nasdaq Stock Market LLC
    Preferred Share Purchase RightsN/AThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     



    Item 2.02    Results of Operations and Financial Condition.
     
    On May 6, 2025, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
    The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.  
    Item 9.01     Financial Statements and Exhibits.
     
    (d) Exhibits
    Exhibit  
    No. Description
    99.1
     
    Press Release dated May 6, 2025.
    104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    KEROS THERAPEUTICS, INC.
    By: /s/ Jasbir Seehra
     
    Jasbir Seehra, Ph.D.
    Chief Executive Officer
    Dated: May 6, 2025

    Get the next $KROS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    6/10/2025$18.00Buy → Neutral
    BofA Securities
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    12/12/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings